Prevalence and treatment of dyslipidemia in canadian primary care: A retrospective cohort analysis

Clinical Therapeutics

Volumn 29, Issue 4, 2007, Pages 742-750

  Petrella, Robert J ^a   Merikle, Elizabeth ^b   Jones, Jared ^a  

^a WESTERN UNIVERSITY   (Canada)

^b PFIZER INC   (United States)

Author keywords

Canadian primary care; cardiovascular risk; dyslipidemia prevalence; low density lipoprotein cholesterol; statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY HEIGHT; BODY WEIGHT; CANADA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DATA BASE; DYSLIPIDEMIA; FEMALE; FITNESS; HIGH RISK PATIENT; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT SELECTION; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SMOKING; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; CANADA; COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREVALENCE; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 34347378697     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.04.009     Document Type: Article

References (30)

1. The growing burden of heart disease and stroke in Canada 2003 (2003), Heart and Stroke Foundation of Canada, Ottawa
2. Murray C.J., and Lopez A.D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349 (1997) 1269-1276
3. Policy Research Division SPDPaPHBHC. Economic burden of illness in Canada, 1998 (2002), Policy Research Division SPDPaPHBHC, Ottawa, Ontario, Canada
4. Choi B.K., and Pak A.W. A method for comparing and combining cost-of-illness studies: An example from cardiovascular disease. Chronic Dis Can. 23 (2002) 47-57
5. [published correction appears in CMAJ. 2003;169:1149]. Genest J., Frohlich J., Fodor G., McPherson R., and Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary ofthe 2003 update. CMAJ 169 (2003) 921-924
6. Fitchett D.H., Leiter L.A., Tardif J.C., et al. Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?. Can J Cardiol. 21 (2005) 85-90
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
8. Gould A.L., Rossouw J.E., Santanello N.C., et al. Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation 97 (1998) 946-952
9. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and metaanalysis. BMJ 326 (2003) 1423
10. Joffres M.R., Kamath T.V., Williams G.R., et al. Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001. Can J Cardiol. 20 (2004) 767-772
11. Kephart G., Sketris I., MacLean D., et al. Management of high blood cholesterol levels in Nova Scotian adults: Comparison with the NCEP II and European clinical practice guidelines. Am J Manag Care. 6 (2000) 1017-1028
12. Spaans J.N., Coyle D., Fodor G., et al. Application of the 1998 Canadian cholesterol guidelines to a military population: Health benefits and cost effectiveness of improved cholesterol management. Can J Cardiol. 19 (2003) 790-796
13. Brown L.C., Johnson J.A., Majumdar S.R., et al. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 171 (2004) 1189-1192
14. Ko D.T., Mamdani M., and Alter D.A. Lipid-lowering therapy with statins in high-risk elderly patients: The treatment-risk paradox. JAMA 291 (2004) 1864-1870
15. Joffres M.R., and MacLean D.R. Comparison of the prevalence of cardiovascular risk factors between Quebec and other Canadian provinces: The Canadian heart health surveys. Ethn Dis 9 (1999) 246-253
16. MacLean D.R., Petrasovits A., Connelly P.W., et al., Canadian Heart Health Surveys Research Group. Plasma lipids and lipoprotein reference values, and the prevalence of dyslipoproteinemia in Canadian adults. Can J Cardiol. 15 (1999) 434-444
17. Fodor J.G., Frohlich J.J., Genest Jr. J.J., and McPherson P.R. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 162 (2000) 1441-1447
18. Petrella R.J., Lattanzio C.N., Derneray A., et al. Can adoption of regular exercise later in life prevent metabolic risk for cardiovascular disease?. Diabetes Care. 28 (2005) 694-701
19. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
20. Available at:. Department of Health and Human Services. National Institutes of Health, National Heart, Blood, and Lung Institute. Framingham Heart Study [NBLI Web site]. Accessed (2007). http://www.nhlbi.nih.gov/about/framingham/index.html
21. [published correction appears in Circulation. 2004;110:763]. Grundy S.M., Cleeman J.I., Merz C.N., et al., National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
22. Kedward J., and Dakin L. A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care. Br J Gen Pract. 53 (2003) 684-689
23. Levy A.R., O'Brien B.J., McMullen E., et al. Rapid increase in statins newly dispensed to Ontario seniors be tween 1994 and 2000. Cant Cardiol 19 (2003) 665-669
24. DeWilde S., Carey I.M., Bremner S.A., et al. Evolution of statin prescribing 1994-2001: A case of agism but not of sexism?. Heart 89 (2003) 417-421
25. O'Meara J.G., Kardia S.L., Armon J.J., et al. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med. 164 (2004) 1313-1318
26. Pearson T.A., Laurora I., Chu H., and Kafonek S. The lipid treatment assessment project (LTAP): A multi center survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 160 (2000) 459-467
27. Vale M.J., Jelinek M.V., Best J.D., and COACH study group. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust. 176 (2002) 211-215
28. Larsen J., Andersen M., Kragstrup J., and Gram L.F. Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998) in a Danish population. Eur J Clin Pharmacol. 57 (2001) 343-348
29. Garcia Ruiz F.J., Marin Ibanez A., Perez-Jiminez F., et al., REALITY Study Group. Current lipid man agement and low cholesterol goal attainment in common daily practice in Spain. The REALITY study. Pharmaco Economics 22 Suppl 3 (2004) 1-12
30. EUROASPIRE II Study GrouptLifestyle and risk factor management and use of drug therapies in coro nary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 22 (2001) 554-572